A detailed history of Hamel Associates, Inc. transactions in Novartis Ag stock. As of the latest transaction made, Hamel Associates, Inc. holds 8,680 shares of NVS stock, worth $854,546. This represents 0.31% of its overall portfolio holdings.

Number of Shares
8,680
Previous 8,645 0.4%
Holding current value
$854,546
Previous $920,000 8.48%
% of portfolio
0.31%
Previous 0.29%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$106.13 - $120.89 $3,714 - $4,231
35 Added 0.4%
8,680 $998,000
Q1 2024

Apr 23, 2024

SELL
$95.27 - $108.47 $47,635 - $54,235
-500 Reduced 5.47%
8,645 $836,000
Q4 2023

Feb 08, 2024

SELL
$92.27 - $101.54 $46,135 - $50,770
-500 Reduced 5.18%
9,145 $923,000
Q1 2023

May 08, 2023

SELL
$80.03 - $92.81 $480 - $556
-6 Reduced 0.06%
9,645 $887,000
Q2 2022

Aug 08, 2022

SELL
$80.52 - $93.75 $67,636 - $78,750
-840 Reduced 8.01%
9,651 $816,000
Q1 2022

May 06, 2022

SELL
$80.11 - $90.62 $304,257 - $344,174
-3,798 Reduced 26.58%
10,491 $921,000
Q4 2021

Feb 08, 2022

SELL
$79.7 - $88.13 $2.12 Million - $2.35 Million
-26,650 Reduced 65.1%
14,289 $1.25 Million
Q3 2021

Nov 08, 2021

SELL
$81.78 - $95.14 $704,861 - $820,011
-8,619 Reduced 17.39%
40,939 $3.35 Million
Q2 2021

Aug 04, 2021

SELL
$85.24 - $94.15 $83,109 - $91,796
-975 Reduced 1.93%
49,558 $4.52 Million
Q1 2021

May 04, 2021

SELL
$83.5 - $98.47 $166,165 - $195,955
-1,990 Reduced 3.79%
50,533 $4.32 Million
Q4 2020

Feb 11, 2021

SELL
$78.07 - $94.43 $47,622 - $57,602
-610 Reduced 1.15%
52,523 $4.96 Million
Q3 2020

Nov 09, 2020

BUY
$82.14 - $91.0 $17,660 - $19,565
215 Added 0.41%
53,133 $4.62 Million
Q2 2020

Aug 10, 2020

SELL
$80.93 - $91.1 $28,325 - $31,884
-350 Reduced 0.66%
52,918 $4.62 Million
Q1 2020

May 07, 2020

BUY
$70.67 - $99.01 $20,494 - $28,712
290 Added 0.55%
53,268 $4.39 Million
Q4 2019

Feb 12, 2020

SELL
$84.35 - $95.37 $55,080 - $62,276
-653 Reduced 1.22%
52,978 $5.02 Million
Q3 2019

Nov 12, 2019

SELL
$85.54 - $94.26 $21,385 - $23,565
-250 Reduced 0.46%
53,631 $4.66 Million
Q2 2019

Aug 05, 2019

SELL
$75.4 - $92.8 $32,422 - $39,904
-430 Reduced 0.79%
53,881 $4.92 Million
Q1 2019

May 01, 2019

BUY
$75.32 - $86.15 $17,700 - $20,245
235 Added 0.43%
54,311 $5.22 Million
Q3 2018

Oct 25, 2018

BUY
$66.94 - $77.43 $92,042 - $106,466
1,375 Added 2.61%
54,076 $4.66 Million
Q2 2018

Aug 10, 2018

SELL
$64.91 - $73.36 $16,876 - $19,073
-260 Reduced 0.49%
52,701 $3.98 Million
Q1 2018

May 03, 2018

SELL
$70.39 - $84.15 $12,318 - $14,726
-175 Reduced 0.33%
52,961 $4.28 Million
Q4 2017

Feb 13, 2018

BUY
$72.33 - $77.64 $723 - $776
10 Added 0.02%
53,136 $4.46 Million
Q3 2017

Nov 14, 2017

SELL
$74.14 - $77.27 $29,656 - $30,908
-400 Reduced 0.75%
53,126 $4.56 Million
Q2 2017

Aug 11, 2017

BUY
N/A
53,526
53,526 $4.47 Million

Others Institutions Holding NVS

About NOVARTIS AG


  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $212B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track Hamel Associates, Inc. Portfolio

Follow Hamel Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hamel Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hamel Associates, Inc. with notifications on news.